PA-EXONE
The ExOne Company (Nasdaq: XONE), the global leader in industrial sand and metal 3D printers using binder jetting technology, today announced that the nickel-based alloy Inconel 718 has been certified as Third-Party Qualified, the company’s highest designation of material readiness for its metal 3D printers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200805005200/en/
Frequently used in the aerospace, energy and automotive industries, Inconel 718 is known for high strength and hardness, with strong resistance to corrosion, chemicals and extreme temperatures ranging from sub-zero to 1300° F. It also has outstanding welding characteristics, and is often used for high-temperature applications, such as jet engines and tooling, or corrosive environments, such as those featuring seawater or acids.
“Today’s qualification of Inconel 718, following on the heels of M2 Tool Steel earlier this year, shows the ExOne R&D team is aggressively delivering new materials for binder jet 3D printing,” said Rick Lucas, ExOne CTO and VP, New Markets. “Our increasing pace of material qualifications is a testament to the strength of our new metal 3D printer systems equipped with Triple ACT, an advanced compaction technology that is essential for binder jetting metals and other materials at high speeds and densities.”
As is the case with Inconel 718, ExOne’s patented Triple ACT enables 3D printing of standard MIM powders, followed by standard sintering profiles and heat treatments, that deliver high-density results consistent with wrought material. Independent testing verifies that Inconel 718 3D printed and sintered by ExOne meets ASTM standard B637-18 .
“ExOne can now transition R&D materials to full qualification as demand increases,” Lucas noted.
ExOne Material Qualification Levels
ExOne has three tiers of material qualification, to signify the varying levels of readiness of materials for binder jet 3D printing applications: R&D, Customer-Qualified and Third-Party Qualified.
Previously, ExOne had recognized Inconel 718 as an R&D material, which meant it had been deemed printable for researchers, supported by ongoing development. The new Third-Party Qualified status means that the material has passed rigorous ExOne tests over multiple builds and has verified material property data from an independent third party.
Customer-Qualified materials are those that have been qualified by ExOne customers with their own standards and are being successfully printed today for their own applications. However, they have not yet earned ExOne’s highest level of qualification for general market readiness.
ExOne has an aggressive roadmap to qualify new materials based on customer demand, and frequently works with major manufacturers to develop new materials to suit specific applications.
To date, 22 metal, ceramic and composite materials are now Third-Party or Customer-Qualified. The full list is available at www.exone.com/metalmaterials .
Additionally, more than two-dozen materials are recognized as R&D ready, including aluminum, which has been fast-tracked for qualification. ExOne believes the ability to 3D print aluminum at high speeds will have a transformative, sustainable effect on the automobile and aerospace industry.
CleanFuse Enables Binder Jetting of Premium Metals
ExOne’s proprietary CleanFuse binder was a critical component in the new qualification of Inconel 718. CleanFuse is a clean-burning binder for 3D printing metals that are sensitive to carbon left behind by other binding agents during sintering.
Binder jetting is a 3D printing process that uses a digital file to quickly inkjet a binder into a bed of powder particles — metal, sand or ceramic — creating a solid part one layer at a time. When printing metals, the final part must be sintered in order to fuse the particles together into a solid object.
When binders don’t burn off cleanly during sintering, carbon residue can alter the chemistry and fundamental performance of some sensitive metals. Consequently, a benefit of 3D printing metals with CleanFuse is preserving consistent part performance, including a part’s ability to be welded. This is critical for aerospace, automotive or defense applications, where parts are often integrated or assembled into a final product.
About ExOne
ExOne is the pioneer and global leader in binder jet 3D printing technology. Since 1995, we’ve been on a mission to deliver powerful 3D printers that solve the toughest problems and enable world-changing innovations. Our 3D printing systems quickly transform powder materials — including metals, ceramics, composites and sand — into precision parts, metalcasting molds and cores, and innovative tooling solutions. Industrial customers use our technology to save time and money, reduce waste, improve their manufacturing flexibility, and deliver designs and products that were once impossible. As home to the world’s leading team of binder jetting experts, ExOne also provides specialized 3D printing services, including on-demand production of mission-critical parts, as well as engineering and design consulting. Learn more about ExOne at www.exone.com or on Twitter at @ExOneCo. We invite you to join with us to #MakeMetalGreen™.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200805005200/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
